Please use this identifier to cite or link to this item:
Title: A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial
Authors: Siriwan Tangjitgamol
Ekkasit Tharavichitkul
Chokaew Tovanabutra
Kanisa Rongsriyam
Tussawan Asakij
Kannika Paengchit
Jirasak Sukhaboon
Somkit Penpattanagul
Apiradee Kridakara
Jitti Hanprasertpong
Kittisak Chomprasert
Sirentra Wanglikitkoon
Thiti Atjimakul
Piyawan Pariyawateekul
Kanyarat Katanyoo
Prapai Tanprasert
Wanwipa Janweerachai
Duangjai Sangthawan
Jakkapan Khunnarong
Taywin Chottetanaprasith
Busaba Supawattanabodee
Prasert Lertsanguansinchai
Jatupol Srisomboon
Wanrudee Isaranuwatchai
Vichan Lorvidhaya
Keywords: Medicine
Issue Date: 1-Jul-2019
Abstract: © 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology. Objective: To compare response rate and survivals of locally advanced stage cervical cancer patients who had standard concurrent chemoradiation therapy (CCRT) alone to those who had adjuvant chemotherapy (ACT) after CCRT. Methods: Patients aged 18–70 years who had International Federation of Gynecology and Obstetrics stage IIB–IVA without para-aortic lymph node enlargement, Eastern Cooperative Oncology Group scores 0–2, and non-aggressive histopathology were randomized to have CCRT with weekly cisplatin followed by observation (arm A) or by ACT with paclitaxel plus carboplatin every 4 weeks for 3 cycles (arm B). Results: Data analysis of 259 patients showed no significant difference in complete responses at 4 months after treatment between arm A (n=129) and arm B (n=130): 94.1% vs. 87.0% (p=0.154) respectively. With the median follow-up of 27.4 months, 15.5% of patients in arm A and 10.8% in arm B experienced recurrences (p=0.123). There were no significant differences of overall or loco-regional failure. However, systemic recurrences were significantly lower in arm B than arm A: 5.4% vs. 10.1% (p=0.029). The 3-year progression-free survival (PFS) and 3-year overall survival (OS) of the patients in both arms were not significantly different. The hazard ratio of PFS and OS of arm B compared to arm A were 1.26 (95% CI=0.82–1.96; p=0.293) and 1.42 (95% CI=0.81–2.49; p=0.221) respectively. Conclusions: ACT with paclitaxel plus carboplatin after CCRT did not improve response rate and survival compared to CCRT alone. Only significant decrease of systemic recurrences with ACT was observed, but not overall or loco-regional failure.
ISSN: 20050399
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.